Does the LTC4S rs730012 C allele increase cysteinyl leukotriene signaling?

The LTC4S rs730012 (-444 A>C) promoter polymorphism is a well-characterized genetic variant that directly influences the biosynthetic pathway of inflammatory lipid mediators.

Molecular mechanisms

• Transcription Factor Binding: The rs730012 C allele alters the LTC4S promoter, creating a putative H4TF-2 transcription factor binding site. This alteration facilitates transcription factor engagement, driving the upregulation of LTC4S mRNA expression rather than modifying the catalytic properties of the enzyme itself.
• Pathway Flux Control: Leukotriene C4 synthase (LTC4S) is the rate-limiting enzyme that conjugates the unstable intermediate leukotriene A4 (LTA4) with glutathione to produce LTC4. Upregulation of LTC4S biases LTA4 partitioning away from alternative pathways (such as LTB4 synthesis) and directly toward cysteinyl leukotrienes (cysLTs).
• Substrate Amplification: The biosynthetic capacity of the pathway is strictly constrained by upstream substrate generation. When arachidonic acid is mobilized by phospholipase A2 (PLA2) and converted to LTA4 via the active 5-LO/FLAP complex, high substrate availability synergizes with elevated LTC4S expression to exponentially amplify downstream cysLT signaling.

Clinical and physiological implications

• Cell and Tissue Specificity: The functional impact of the C allele is highly context-dependent, manifesting robustly in stimulated immune cells (such as peripheral blood eosinophils) and vascular tissues, where it correlates with elevated ex vivo LTC4 production.
• Inflammatory Pathology: This genotype is clinically linked to conditions like asthma, aspirin-exacerbated respiratory disease, and vascular inflammation. Furthermore, C-containing promoter haplotypes display heightened transcriptional responsiveness to dexamethasone and modulate patient responses to leukotriene receptor antagonists.

Bottom line

• The LTC4S rs730012 C allele creates a promoter-binding site for the H4TF-2 transcription factor, upregulating enzyme expression. When arachidonic acid availability is elevated, this increased expression shifts metabolic flux toward the rate-limiting synthesis of cysteinyl leukotrienes, significantly amplifying pro-inflammatory signaling.